Developing an mRNA therapy for Duchenne muscular dystrophy
Drug Target Review
MARCH 21, 2024
There are a few approved therapies for DMD including four exon-skipping drugs and one AAV-microdystrophin drug, which uses a shortened version of dystrophin. AAV-based therapies often can’t be dosed more than once due to concerns about an immune response. Of note, mRNA is redosable as opposed to AAV. Human molecular genetics.
Let's personalize your content